Speaker(s): 

Dave Dixon, PharmD, FACC, FAHA, FCCP, FNLA, BCACP, CLS, Staff Member, VCU School of Pharmacy- has reported the following disclosure: Boehringer Ingelheim ["Research Grant"].

Moderator(s): 

Daniel Longyhore, PharmD, Ed.D., BCACP, Staff Member, Geisinger - has nothing to disclose.   

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• interpret a standard lipid profile for assessing cardiovascular risk and the management of lipid disorders.
• compare and contrast the role of LDL-C, non-HDL-C, and ApoB as treatment targets.
• explain the utility of measuring Lp(a) and its potential as a treatment target.    

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Daniel Longyhore, PharmD, Ed.D., BCACP; Eric Wright, PharmD, MPH; Melissa Kern, MPH; Lisabeth Karetsky, CPhT and Nichole Varela Gonzalez have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose.

Courtney Hugo, MEd, MSLS and Roxanna Larsen, MS, LAT, ATC: have nothing to disclose.

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.